In a recent study by Ma et al. [18] in 2022, among 52 possible targets, TNF, IL-6, CD4, EGFR, IL1B, IL10, AKT1, VEGFA, TP53, and IL2 had the highest degree values, indicating that these targets are important in the development of OLP and are expected to be targeted for clinical treatment of OLP. This evidence concerns the gene AKT1 and oral lichen planus.